The effect of recombinant and plasma-derived prothrombin on prothrombin time in human plasma
Standard
The effect of recombinant and plasma-derived prothrombin on prothrombin time in human plasma. / Hansson, K M; Björkqvist, J; Deinum, J.
In: INT J LAB HEMATOL, Vol. 37, No. 3, 06.2015, p. 357-64.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The effect of recombinant and plasma-derived prothrombin on prothrombin time in human plasma
AU - Hansson, K M
AU - Björkqvist, J
AU - Deinum, J
N1 - © 2014 John Wiley & Sons Ltd.
PY - 2015/6
Y1 - 2015/6
N2 - INTRODUCTION: When investigating coagulation assays to measure the effect of infused prothrombin (FII) in in vivo coagulopathy models, we found that addition of FII, plasma-derived human FII (pd-hFII) or recombinant human FII (r-hFII), to normal plasma resulted in a concentration-dependent increase in prothrombin time (PT) initiated with Innovin(®) .METHODS: The effect on PT by addition to plasma of either pd-hFII or r-hFII, using different commercial PT reagents, was studied both by turbidimetry and viscometry.RESULT: Addition of FII to plasma resulted in increased PT when initiated with Innovin(®) : PT increased with 20% by doubling the concentration. The prolongation of PT became more pronounced with 2-6000 times diluted Innovin(®) . However, by adjustment of the final free Ca(2+) concentration in the assay with diluted Innovin(®) from 8.3 to 1.3 mmol/L, no FII-dependent increase in PT was found. In contrast, no prolongation of PT was found with other commercial PT reagents. A KM = 3 nmol/L was obtained with pd-hFII, respectively, r-hFII with FII-depleted plasma using Thromborel(®) to initiate PT.CONCLUSION: At normal plasma concentration of FII, addition of FII should not have an effect on PT. The prolonged PT with Innovin(®) , but not with other PT reagents, at supranormal FII concentration is an artefact.
AB - INTRODUCTION: When investigating coagulation assays to measure the effect of infused prothrombin (FII) in in vivo coagulopathy models, we found that addition of FII, plasma-derived human FII (pd-hFII) or recombinant human FII (r-hFII), to normal plasma resulted in a concentration-dependent increase in prothrombin time (PT) initiated with Innovin(®) .METHODS: The effect on PT by addition to plasma of either pd-hFII or r-hFII, using different commercial PT reagents, was studied both by turbidimetry and viscometry.RESULT: Addition of FII to plasma resulted in increased PT when initiated with Innovin(®) : PT increased with 20% by doubling the concentration. The prolongation of PT became more pronounced with 2-6000 times diluted Innovin(®) . However, by adjustment of the final free Ca(2+) concentration in the assay with diluted Innovin(®) from 8.3 to 1.3 mmol/L, no FII-dependent increase in PT was found. In contrast, no prolongation of PT was found with other commercial PT reagents. A KM = 3 nmol/L was obtained with pd-hFII, respectively, r-hFII with FII-depleted plasma using Thromborel(®) to initiate PT.CONCLUSION: At normal plasma concentration of FII, addition of FII should not have an effect on PT. The prolonged PT with Innovin(®) , but not with other PT reagents, at supranormal FII concentration is an artefact.
KW - Blood Proteins
KW - Calcium
KW - Humans
KW - Prothrombin
KW - Prothrombin Time
KW - Recombinant Proteins
KW - Thromboplastin
U2 - 10.1111/ijlh.12293
DO - 10.1111/ijlh.12293
M3 - SCORING: Journal article
C2 - 25212252
VL - 37
SP - 357
EP - 364
JO - INT J LAB HEMATOL
JF - INT J LAB HEMATOL
SN - 1751-5521
IS - 3
ER -
